Form4insider filings, from the source

SEC Form 4 · accession 0001708138-17-000017

REGENERON PHARMACEUTICALS, INC. · REGN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
P Roy Vagelos
Officer — Chairman of the Board · Director
Period of report
Aug 21, 2017
Accepted (ET)
Aug 23, 2017 · 4:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1Aug 21, 2017S22,118$470.23D363,638D
Common StockF2Aug 21, 2017S1,951$471.09D361,687D
Common StockF3Aug 21, 2017S200$472.16D361,487D
Common StockF4Aug 22, 2017S400$470.64D361,087D
Common StockF5Aug 22, 2017S600$471.63D360,487D
Common StockF6Aug 22, 2017S900$472.67D359,587D
Common StockF7Aug 22, 2017S200$473.65D359,387D
Common StockF8Aug 22, 2017S2,400$474.64D356,987D
Common StockF9Aug 22, 2017S5,610$475.49D351,377D
Common StockF10Aug 22, 2017S5,744$476.46D345,633D
Common StockF11Aug 22, 2017S3,473$477.52D342,160D
Common StockF12Aug 22, 2017S1,600$478.51D340,560D
Common StockF13Aug 22, 2017S600$479.63D339,960D
Common StockF14Aug 22, 2017S5,250$480.62D334,710D
Common StockF15Aug 22, 2017S4,661$481.37D330,049D
Common StockAug 22, 2017S400$482.72D329,649D
Common StockAug 22, 2017S106$483.00D329,543D
Common Stockholding———2,300IBy 401(k) Plan
Common Stockholding———150,285Iby CLAT
Common Stockholding———83,652Iby Spouse as Trustee
Common StockF16holding———1,203Iby trust for grandch

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses